Global Scleroderma Diagnostics and Therapeutics Market to Reach $2.8 Billion by 2030
The global market for Scleroderma Diagnostics and Therapeutics estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$2.8 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2022-2030. Localized, one of the segments analyzed in the report, is projected to record 4.6% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Systemic segment is readjusted to a revised 3.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $592.9 Million, While China is Forecast to Grow at 3.8% CAGR
The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$592.9 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$486.3 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 3.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.Select Competitors (Total 42 Featured) -
- Actelion Pharmaceuticals Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Corbus Pharmaceuticals Holdings, Inc.
- Cumberland Pharmaceuticals, Inc.
- Cytori Therapeutics, Inc.
- Gilead Sciences, Inc.
- Pfizer, Inc.
- Sanofi SA
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Scleroderma Diagnostics and Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Immunosuppressive Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Endothelin receptor antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Scleroderma Diagnostics and Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 11: World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Localized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Systemic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 22: USA 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 23: USA Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 25: USA 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: Canada 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 29: Canada Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: Canada 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- JAPAN
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 32: Japan Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: Japan 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 35: Japan Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: Japan 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- CHINA
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 38: China Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: China Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: China 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 41: China Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: China 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- EUROPE
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 44: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 47: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- FRANCE
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 53: France Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: France Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: France 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 56: France Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 58: France 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- GERMANY
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 59: Germany Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 60: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 61: Germany 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 62: Germany Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 64: Germany 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- ITALY
- Table 65: Italy Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 66: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 67: Italy 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 68: Italy Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 70: Italy 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 71: UK Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 72: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 73: UK 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 74: UK Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 76: UK 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 77: Rest of Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 78: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 79: Rest of Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 82: Rest of Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 84: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 85: Asia-Pacific 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 87: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 88: Asia-Pacific 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 89: Rest of World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 91: Rest of World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 92: Rest of World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 94: Rest of World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Actelion Pharmaceuticals Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Corbus Pharmaceuticals Holdings, Inc.
- Cumberland Pharmaceuticals, Inc.
- Cytori Therapeutics, Inc.
- Gilead Sciences, Inc.
- Pfizer, Inc.
- Sanofi SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 194 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2 Billion |
Forecasted Market Value ( USD | $ 2.8 Billion |
Compound Annual Growth Rate | 4.3% |
Regions Covered | Global |